Claims for Patent: 5,061,703

Summary for Patent: 5,061,703

Title:	Adamantane derivatives in the prevention and treatment of cerebral ischemia
Abstract:	A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
Inventor(s):	Bormann; Joachim (Frankfurt, DE), Gold; Markus R. (Nauheim, DE), Schatton; Wolfgang (Eschborn, DE)
Assignee:	Merz + Co. GmbH & Co. (Frankfurt am Main, DE)
Application Number:	07/508,109
Patent Claims:	1. A method for the prevention or treatment of cerebral ischemia comprising the step of administering, to a patient in need thereof, an effective amount of an adamantane derivative of the general formula ##STR5## wherein R.sub.1 and R.sub.2 are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof. 2. A method according to claim 1, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen. 3. A method according to claim 2, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen, and R.sub.3 and R.sub.4 are methyl. 4. A method according to claim 2, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen, and R.sub.3 and R.sub.4 are ethyl. 5. A method according to claim 1, wherein R.sub.1, R.sub.2, R.sub.4 and R.sub.5 are hydrogen, and R.sub.3 is ethyl, isopropyl, or cyclohexyl. 6. A method according to claim 1, wherein R.sub.2 and R.sub.5 are hydrogen. 7. A method according to claim 6, wherein R.sub.3 and R.sub.4 are methyl, R.sub.2 and R.sub.5 are hydrogen and R.sub.1 is methyl or ethyl. 8. A method according to claim 1, wherein R.sub.1 and R.sub.2 are hydrogen. 9. A method according to claim 8, wherein R.sub.1 and R.sub.2 are hydrogen, R.sub.3 is ethyl, and R.sub.5 and R.sub.4 are methyl. 10. A method according to claim 1 for the treatment of Alzheimer's disease. 11. A method of claim 1, wherein the adamantane derivative is administered in an effective cerebral ischemia-alleviating or preventive amount. 12. A method of claim 11, wherein the adamantane derivative is administered in the form of a composition containing the same together with a pharmaceutically-acceptable carrier or diluent. 13. A method of claim 11, wherein the adamantane derivative is administered in an amount effective to prevent degeneration and loss of nerve cells after ischemia.